Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy

Breast Cancer Research

Table 1 Binding selectivity (geometric mean) of candidate podocalyxin antibodies compared with isotype control ^a

mAb name	HUVEC	MCF7	MDA-MB-231	T47D	CAOV-3	OVCAR-3	OVCAR-10	A-172	HEK293
Isotype	489	657	477	697	767	629	653	644	446
PODOC1	44,611	60,805	91,909	1,498	48,817	16,502	2,834	169,600	28,225
PODOC2	3,231	1,962	26,513	2,036	37,683	9,189	645	49,862	459
PODOC3	2,103	9,399	2,939	818	10,472	8,355	1,803	181,211	3,869
PODOC4	113,144	15,161	143,135	34,559	125,223	29,862	564	333,980	2,679
PODOC5	40,490	25,055	80,312	1,853	31,657	9,824	1,756	172,233	27,144
PODOC6	994	1,239	4,744	2,685	1,670	1,350	1,165	2,760	485
PODOC7	21,700	22,330	57,626	1,010	37,668	11,058	2,539	278,032	13,886
PODOC8	23,207	45,707	1,950	566	52,200	8,805	2,731	263,842	5,056

^aHEK293, Human embryonic kidney 293 cells; HUVEC, Human umbilical vascular endothelial cells; mAb, Monoclonal antibody; PODOC, Podocalyxin antibody.

ISSN: 1465-542X